Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay
Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM’s ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes.
Following a rigorous review by the Clinical Laboratory Evaluation Program (CLEP), the Department of Health has determined that LabPMM meets the required standards and granted approval to offer the FLT3 ITD MRD Assay in New York State. This approval underscores the assay’s robust analytical performance and clinical utility in the detection of MRD in patients with FLT3 ITD-mutated AML.
"This milestone reflects our commitment to improve patient lives with precision diagnostics," said Jordan Thornes, V.P. Global Clinical Operations at LabPMM®. "With New York state’s approval, we are immediately able to extend access to this important test to clinicians and patients throughout one of the nation’s largest and most rigorously regulated laboratory testing markets."
The FLT3 ITD MRD assay is a targeted, highly sensitive next-generation sequencing (NGS) assay that detects and tracks internal tandem duplication (ITD) mutations in the fms-like tyrosine kinase 3(FLT3) gene at an allele sensitivity of 5 x 10-5. FLT3 ITD mutations are the most prevalent mutations found in AML and are characterized by an aggressive phenotype with a high prevalence of relapse. 1,2 Detection of residual FLT3 ITD allows clinicians to identify patients that can benefit from continuation or modification of treatment and predict clinical outcomes. 1,2,3
For more information about the FLT3 ITD MRD Assay and LabPMM’s full test menu, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
About Invivoscribe
Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the US, Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
- Dillon, L., et al. JAMA. 2023;329(9):745-755.
- Dillon, L., et al. JAMA Oncol. 2024;10(8):1104-1110.
- Levis, MJ et al. (2018) Blood Advances. 2: 825-831.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421272115/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting22.4.2025 10:37:00 CEST | Press release
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual Meeting (AACR) 2025 being held in Chicago April 25-30, 2025. In the poster, entitled “Preferential tumor uptake and retention of EGL-001, an anti-CTLA4-IL2 mutein fusion antibody achieving selective tumor Treg depletion”. Egle Therapeutics unveils preclinical biodistribution data on EGL-001, a novel anti-CTLA4-IL2 mutein fusion antibody designed to selectively deplete tumor-infiltrating regulatory T cells (Tregs). EGL-001 mode of action combines competitive inhibition of IL-2 signaling and potent downregulation of surface CD25, leading to induction of Treg apoptosis. In vivo EGL-001 preferentially bound to the surface of Tregs due to their high CTLA-4 and CD25 expression and depleted them from the tumor microenvironment without affecting other immun
The Smarter E Europe: Launch of Special Exhibit on Bidirectional Charging – the Energy Transition Gains Traction22.4.2025 09:00:00 CEST | Press release
Electricity from renewable sources has become the new normal – in Germany alone, around 60 percent of net electricity generation came from renewables in 2024. But the growing volume of green power is posing new challenges for energy supply: The integration into the existing system urgently requires more flexibility. A Euroelectric/EY study forecasts a doubling of daily European flexibility demand by 2030 compared to 2021, potentially reaching 1.8 TWh daily (137 TWh annually), a substantial rise from the prior 1.5 TWh weekly demand. Electric vehicle (EV) batteries are identified as a key flexibility solution, potentially offering around 116 TWh capacity within five years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417476684/en/ A special exhibition at The smarter E Europe is dedicated to bidirectional charging. ©Solar Promotion GmbH Dr. Frank Spennemann, Senior Manager Charging Solutions Energy at Mercedes-Benz, has a
A new weapon in the global fight against malaria22.4.2025 09:00:00 CEST | Press release
World Health Organization prequalifies Syngenta’s innovative insecticide Sovrenta® Malaria is one of the world’s most deadly diseases, and it is becoming more pervasive – despite decades of effort and some successes on the path to eradicating it. According to the World Health Organization (WHO), malaria infected 263 million people and killed nearly 600,000 people in 2023 – 75% of whom were children under the age of 5. Of those afflicted, 94% are in Africa – where malaria crushes communities and can cripple economies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422328472/en/ Syngenta Vector Control: A leading role in the prevention of vector-borne disease transmission through its portfolio of mosquito control products Spread by parasites in infected mosquitoes that are highly adept at evolving, malaria’s rise reflects the reality of insecticide resistance and the difficulties developing new solutions. The effective cont
IFF Pharma Solutions to Showcase Plant-Based Dietary Supplement Ingredients and Technical Expertise at Vitafoods™ Europe 202522.4.2025 08:00:00 CEST | Press release
Improving the World of Dietary Supplements with a Breadth of Proven Brands. IFF (NYSE: IFF) Pharma Solutions is excited to announce its participation at Vitafoods™ Europe 2025, the premier global nutraceutical event. The team will showcase its cutting-edge dietary supplement plant-based ingredients portfolio of innovative and trusted brands including SeaGel®, VERDIGEL™ SC, GRINDSTED® Pectin Premium, Ac-Di-Sol®, Avicel®, Accelerate®, and METHOCEL™ in hall 4 at booth 4F25, May 20-22, at the Fira Barcelona Gran Via. "We are excited to highlight vivid examples of how our high-quality functional ingredients and technical expertise help our customers produce superior supplements," said Firat Nalbantoglu, EMEA commercial leader, IFF Pharma Solutions. "Our technical and commercial experts look forward to offering solutions for formulation and processing challenges. If you aim to enhance efficacy and bioavailability in your dietary supplements, we invite you to discover new possibilities with u
Venture Global Announces Closing of $2,500,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC21.4.2025 23:00:00 CEST | Press release
Venture Global Inc. (“Venture Global”) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $2,500,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 7.50% senior secured notes due 2033 in an aggregate principal amount of $1,250,000,000 (the “2033 Notes”) and (ii) a series of 7.75% senior secured notes due 2035 in an aggregate principal amount of $1,250,000,000 (the “2035 Notes” and, together with the 2033 Notes, the “Notes”). The 2033 Notes will mature on May 1, 2033 and the 2035 Notes will mature on May 1, 2035. VGPL intends to use the net proceeds from the offering to (i) prepay certain amounts outstanding under VGPL’s existing senior secured first lien credit facilities (the “Existing Credit Facilities”) and (ii) pay fees and expenses in connection with the offering. The notes are guaranteed by Venture Global Gator Express, LLC (VGPL’s affiliate). The Notes are secur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom